Your browser doesn't support javascript.
loading
B-Cell Regeneration Profile and Minimal Residual Disease Status in Bone Marrow of Treated Multiple Myeloma Patients.
Mendonça de Pontes, Robéria; Flores-Montero, Juan; Sanoja-Flores, Luzalba; Puig, Noemi; Pessoa de Magalhães, Roberto J; Corral-Mateos, Alba; Salgado, Anna Beatriz; García-Sánchez, Omar; Pérez-Morán, José; Mateos, Maria-Victoria; Burgos, Leire; Paiva, Bruno; Te Marvelde, Jeroen; van der Velden, Vincent H J; Aguilar, Carlos; Bárez, Abelardo; García-Mateo, Aranzazú; Labrador, Jorge; Leoz, Pilar; Aguilera-Sanz, Carmen; Durie, Brian; van Dongen, Jacques J M; Maiolino, Angelo; Sobral da Costa, Elaine; Orfao, Alberto.
Afiliación
  • Mendonça de Pontes R; Internal Medicine Postgraduate Program, Faculty of Medicine, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro 21941-617, Brazil.
  • Flores-Montero J; Cytometry Service, Institute of Paediatrics and Puericultura Martagão Gesteira (IPPMG), Faculty of Medicine, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro 21941-912, Brazil.
  • Sanoja-Flores L; Translational and Clinical Research Program, Cancer Research Center (IBMCC, USAL-CSIC), Cytometry Service (NUCLEUS) and Department of Medicine, University of Salamanca, Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain.
  • Puig N; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) (CB16/12/00400, CB16/12/00233, CB16/12/00369, CB16/12/00489 and CB16/12/00480), Instituto Carlos III, 28029 Madrid, Spain.
  • Pessoa de Magalhães RJ; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) (CB16/12/00400, CB16/12/00233, CB16/12/00369, CB16/12/00489 and CB16/12/00480), Instituto Carlos III, 28029 Madrid, Spain.
  • Corral-Mateos A; Institute of Biomedicine of Seville, Department of Hematology, University Hospital Virgen del Rocío of the Consejo Superior de Investigaciones Científicas (CSIC), University of Seville, 41013 Seville, Spain.
  • Salgado AB; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) (CB16/12/00400, CB16/12/00233, CB16/12/00369, CB16/12/00489 and CB16/12/00480), Instituto Carlos III, 28029 Madrid, Spain.
  • García-Sánchez O; Service of Hematology, University Hospital of Salamanca (USAL) and IBSAL, 37007 Salamanca, Spain.
  • Pérez-Morán J; Department of Internal Medicine, University Hospital Clementino Fraga Filho, Faculty of Medicine, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro 21941-617, Brazil.
  • Mateos MV; Translational and Clinical Research Program, Cancer Research Center (IBMCC, USAL-CSIC), Cytometry Service (NUCLEUS) and Department of Medicine, University of Salamanca, Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain.
  • Burgos L; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) (CB16/12/00400, CB16/12/00233, CB16/12/00369, CB16/12/00489 and CB16/12/00480), Instituto Carlos III, 28029 Madrid, Spain.
  • Paiva B; Internal Medicine Postgraduate Program, Faculty of Medicine, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro 21941-617, Brazil.
  • Te Marvelde J; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) (CB16/12/00400, CB16/12/00233, CB16/12/00369, CB16/12/00489 and CB16/12/00480), Instituto Carlos III, 28029 Madrid, Spain.
  • van der Velden VHJ; Service of Hematology, University Hospital of Salamanca (USAL) and IBSAL, 37007 Salamanca, Spain.
  • Aguilar C; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) (CB16/12/00400, CB16/12/00233, CB16/12/00369, CB16/12/00489 and CB16/12/00480), Instituto Carlos III, 28029 Madrid, Spain.
  • Bárez A; Service of Hematology, University Hospital of Salamanca (USAL) and IBSAL, 37007 Salamanca, Spain.
  • García-Mateo A; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) (CB16/12/00400, CB16/12/00233, CB16/12/00369, CB16/12/00489 and CB16/12/00480), Instituto Carlos III, 28029 Madrid, Spain.
  • Labrador J; Service of Hematology, University Hospital of Salamanca (USAL) and IBSAL, 37007 Salamanca, Spain.
  • Leoz P; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) (CB16/12/00400, CB16/12/00233, CB16/12/00369, CB16/12/00489 and CB16/12/00480), Instituto Carlos III, 28029 Madrid, Spain.
  • Aguilera-Sanz C; Centro de Investigación Médica Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), Clínica Universidad de Navarra, 31008 Pamplona, Spain.
  • Durie B; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) (CB16/12/00400, CB16/12/00233, CB16/12/00369, CB16/12/00489 and CB16/12/00480), Instituto Carlos III, 28029 Madrid, Spain.
  • van Dongen JJM; Centro de Investigación Médica Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), Clínica Universidad de Navarra, 31008 Pamplona, Spain.
  • Maiolino A; Department of Immunology, Erasmus MC, (EMC) University Medical Center Rotterdam, 3015 GA Rotterdam, The Netherlands.
  • Sobral da Costa E; Department of Immunology, Erasmus MC, (EMC) University Medical Center Rotterdam, 3015 GA Rotterdam, The Netherlands.
  • Orfao A; Department of Hematology, Hospital General de Santa Bárbara, 42005 Soria, Spain.
Cancers (Basel) ; 13(7)2021 Apr 03.
Article en En | MEDLINE | ID: mdl-33916787
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Cancers (Basel) Año: 2021 Tipo del documento: Article País de afiliación: Brasil Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Cancers (Basel) Año: 2021 Tipo del documento: Article País de afiliación: Brasil Pais de publicación: Suiza